Industry-Sponsored Research Week

Rutgers and DuPont ink deal for microbiome modulation in cancer treatment


By David Schwartz
Published: July 28th, 2020

The Center for Advanced Biotechnology and Medicine (CABM) at Rutgers University announced a research collaboration in microbiome science with DuPont Nutrition & Biosciences (DuPont). The two-year research partnership will focus on improving the benefit/risk ratio of chemotherapy by decreasing gut inflammation caused by chemotherapy via modulation of the microbiome.

Recent studies demonstrate that the microbiome plays an important role in gut inflammation, and that oral intake of oncology drugs can induce enterocolitis. The researchers will study whether the administration of beneficial microbes may lead to improving overall patient care and comfort while undergoing cancer treatment.

“We are privileged to be working with Dr. Martin J. Blaser, Dr. Fang Liu and their team at Rutgers on a project targeted at improving patient care for those undergoing chemotherapy, and to combine world-class science from Dr. Blaser and his team with our broad portfolio of microbes, said Sébastien Guéry, PhD, who heads up DuPont’s Human Microbiome Venture (HMV).

That program was launched in 2017 to develop next-generation microbiome solutions for improved health and wellness. HMV is designed to accelerate product development to complement its existing portfolio and build on DuPont’s strong expertise in prebiotics, microbes, proteins and enzymes use for human health.

“We are delighted to further develop our relationship with DuPont for the benefit of human health,” said CABM director Martin J. Blaser. “The interaction of the microbiome with cancer is an important frontier, with important leads already. Our project is aimed to discover new ways to improve cancer therapies.”

Source: DuPont

Posted under: University-Industry Engagement Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment